Archive for the ‘Dr. Lockhart’ Category
EMERGENT BIOSOLUTIONS ANNOUNCES DR. STEPHEN LOCKHART JOINS COMPANY TO LEAD COMMERCIAL PRODUCT DEVELOPMENT SUBSIDIARY
Dr. Lockhart Brings Top-Tier Pharma Leadership to Development of Company’s Commercial Product Portfolio
ROCKVILLE, MD, October 18, 2007—Emergent BioSolutions Inc. (NYSE: EBS) announced today that Dr. Stephen Lockhart has been appointed President, Emergent Product Development UK. Dr. Lockhart will be based at the company’s office located in Wokingham, England, and his responsibilities will include providing [...]
Posted on August 3, 2009 at 5:45 pm by admin · Permalink
· Leave a comment
In: Biothrax, Chief executive officer, Dr. Lockhart, Emergent BioSolutions, Fuad El-Hibri, U.S. Department Of Health And Human Services, U.S. Food and Drug Administration · Tagged with: Biotechnology and Pharmaceuticals, Business, Cambridge University, Clinical trial, Pharmaceuticals, Private Securities Litigation Reform Act, Royal College of Physicians, U.S. Food and Drug Administration
In: Biothrax, Chief executive officer, Dr. Lockhart, Emergent BioSolutions, Fuad El-Hibri, U.S. Department Of Health And Human Services, U.S. Food and Drug Administration · Tagged with: Biotechnology and Pharmaceuticals, Business, Cambridge University, Clinical trial, Pharmaceuticals, Private Securities Litigation Reform Act, Royal College of Physicians, U.S. Food and Drug Administration